BioCryst Pharmaceuticals Inc. (BCRX)
Wall Street Analysts Think BioCryst (BCRX) Could Surge 117.96%: Read This Before Placing a Bet
The consensus price target hints at an 118% upside potential for BioCryst (BCRX). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
BioCryst (BCRX) Surges 8.1%: Is This an Indication of Further Gains?
BioCryst (BCRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might help the stock continue moving higher in the near term.
BioCryst scraps internal drug discovery programs, leans on partnerships to cut costs
BioCryst Pharmaceuticals said on Monday it would wind down its internal drug discovery programs and close its Alabama research facility by the end of 2026, as it pivots to external partnerships to build its rare-disease pipeline and streamline expenses.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Bank of America Global Healthcare Conference 2026 Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2026 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Beats Revenue Estimates
BioCryst Pharmaceuticals (BCRX) came out with a quarterly loss of $0.03 per share versus the Zacks Consensus Estimate of $0.06. This compares to break-even earnings per share a year ago.
Avoro Capital Advisors LLC Trims Stock Position in BioCryst Pharmaceuticals, Inc. $BCRX
Avoro Capital Advisors LLC reduced its position in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) by 72.2% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,250,000 shares of the biotechnology company's stock after selling 3,250,000 shares during the period.
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Q4 2025 Earnings Call Transcript
BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy?
BioCryst (BCRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
BioCryst Pharmaceuticals, Inc. (BCRX) Presents at Jefferies London Healthcare Conference 2025 Transcript
BioCryst Pharmaceuticals, Inc. ( BCRX ) Jefferies London Healthcare Conference 2025 November 19, 2025 12:00 PM EST Company Participants Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Maurice Raycroft - Jefferies LLC, Research Division Presentation Maurice Raycroft Jefferies LLC, Research Division Hi, everyone. My name is Maury Raycroft, and I'm one of the biotech analysts at Jefferies.
BioCryst Pharmaceuticals, Inc. (BCRX) Q3 2025 Earnings Call Transcript
BioCryst Pharmaceuticals, Inc. ( BCRX ) Q3 2025 Earnings Call November 3, 2025 8:30 AM EST Company Participants Nick Wilder Jon Stonehouse - CEO & Executive Director Charles Gayer - President & Chief Commercial Officer William Sheridan - Chief Development Officer Babar Ghias - CFO & Head of Corporate Development Conference Call Participants Laura Chico - Wedbush Securities Inc., Research Division Stacy Ku - TD Cowen, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Wolleben - Citizens JMP Securities, LLC, Research Division John Todaro - Needham & Company, LLC, Research Division Huidong Wang - Barclays Bank PLC, Research Division Presentation Operator Good day, and welcome to BioCryst Third Quarter 2025 Earnings Conference Call. [Operator Instructions] Please note this event is being recorded.
